Business
NetworkNewsWire Announces Publication on Innovative Research Being Developed on Cannabinoid-Based Therapies, Drugs
New York, New York--(Newsfile Corp. - November 17, 2017) - NetworkNewsWire ("NNW"), a mult...
About this update from Infield Minerals Corp
[{"type":"text","content":"NetworkNewsWire Announces Publication on Innovative Research Being Developed on Cannabinoid-Based Therapies, DrugsNew York, New York--(Newsfile Corp. - November 17, 2017) - NetworkNewsWire (\"NNW\"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.The publication, titled, \"Innovation Drives Value for Leading Cannabis Biotechs,\" features a discussion about the increasing demand for therapeutic applications of cannabinoid-based drugs for pain relief, suppression of nausea and appetite stimulation, as well as for symptomatic treatment of various life-changing diseases.To view the full publication, visit: https://www.networknewswire.com/innovation-drives-value-leading-cannabis-biotechs/\"While other biotech companies instead favor partnerships with pharmaceutical raw material suppliers for their cannabinoid supply, InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) utilizes its proprietary biosynthesis process to manufacture any of the 90+ individual cannabinoids found in cannabis. The company's computer-based platform bolsters this production capability by using bioinformatic algorithms to match individual cannabinoids to specific diseases, thereby identifying potential therapeutic targets for its drug development programs.\"InMed's innovative approach to bioinformatics and biosynthesis is groundbreaking, and the company has already filed a provisional patent to protect its cannabinoid biosynthetic process. InMed is currently working on scaling up its manufacturing capability, pivoting from the success of its proprietary laboratory-based systems. To assist with its advancing position in the market, InMed engaged as a consultant Ben Paterson, P.E., a professional engineer with extensive experience in the development of purification and manufacturing processes in the pharmaceutical industry (http://nnw.fm/9Bzoh).About InMedInMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts rese...